https://www.thebodypro.com/category/elvitegravir-vitekta

Elvitegravir (Vitekta)

The Latest

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors Img
Neurocognitive

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

Case Report of Capsulitis With Elvitegravir and Cobicistat (EVG/c) Img

Case Report of Capsulitis With Elvitegravir and Cobicistat (EVG/c)

Although the painful joint condition was associated with early protease inhibitors (predominantly indinavir), a recent case report now links the condition to the integrase inhibitor elvitegravir/c (EVG/c).

Neurological Side Effects With Integrase Inhibitors Cause Discontinuations in Clinical Practice Img
Neurocognitive

Neurological Side Effects With Integrase Inhibitors Cause Discontinuations in Clinical Practice

An analysis from use of integrase inhibitors in clinical practice reported significantly higher rates of discontinuations related to side effects than seen in clinical studies and includes neurologial complications with dolutegravir.

Elvitegravir in Children and Adolescents Img
Conference Coverage

Elvitegravir in Children and Adolescents

Three posters at CROI 2015 showed new pediatric elvitegravir data. The posters described preliminary safety in the 6-to-12-year-old age group, and safety, efficacy, pharmacokinetics and resistance in 12-to-18 year olds receiving elvitegravir in fixed...

New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ... Img
News

New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ...

"If you're wondering what the big deal is [about the approvals of stand-alone cobicistat and elvitegravir], welcome to the club," Paul Sax, M.D., writes.

Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs Img
News

Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs

With this approval, each component of the single-tablet regimen Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) is now green-lighted for use separately in HIV treatment regimens in the U.S.

Promo Image
News

Gilead Receives Complete Response Letters From U.S. FDA for Elvitegravir and Cobicistat

Foster City, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has received Complete Response Letters from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for elvitegravir...

Promo Image
Conference Coverage

Elvitegravir vs. Raltegravir: 96-Week Phase III Results in Treatment-Experienced Patients

Richard Elion from Whitman-Walker Health in Washington presented updated 96 week results from the phase 3 head-to-head study of elvitegravir vs raltegravir.1

The 48 week results, first presented at the IAS conference in Rome last year showed elviteg...